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Purpose: Despite a sizeable and continuously growing literature on osteopontin and cancer the molecule has not
yet found entry into clinical diagnostics. Our identification of spliced variants that are more specific for cancer than
the full-length transcript has opened new possibilities for reaching this goal.
Methods: Here we have developed a real-time RT-PCR blood test and evaluated it in a pilot study of breast, lung,
pancreatic, gynecologic, and other cancers, compared to non-cancer controls.
Results: Osteopontin-b was increased in lung cancers and pancreatic cancers. When applying a cutoff of 2
standard deviations above normal, elevation in osteopontin-b transcripts detected over 40% of lung cancers.
Osteopontin-c was increased in gynecologic and pancreatic cancers. Elevation in osteopontin-c of 2 standard
deviations above the normal mean value also detected a fraction of breast cancers and lung cancers, suggesting
heterogeneity within those types of tumors. Specifically, breast carcinomas were associated with significantly higher
levels of osteopontin-c mRNA in the blood than carcinomas in situ. In lung cancer patients, the osteopontin-c
blood RNA levels had an increasing trend with tumor grade.
Conclusions: Osteopontin-b and -c in the blood are biomarkers for distinct cancers. Our investigations may have
bearing on cancer screening and diagnosis.
Keywords: Biomarker, Blood analysis, Lung cancer, Breast cancer, Cancer progressionIntroduction
Reliable blood tests for early detection and monitoring
of progression are a holy grail in cancer diagnostics.
They require the sufficiently abundant presence of a
molecule that is uniquely associated with the presence
or the progression of a particular type of cancer or mul-
tiple cancers. While a plethora of biomarkers has been
described in the literature, few have achieved routine
clinical use. Among them, PSA for the early detection as
well as treatment monitoring of prostate cancer stands
out. CEA is elevated in the blood of patients with co-
lorectal, gastric, pancreatic, lung or breast carcinomas.
CEA is mainly used to identify recurrence after surgical
resection, because the blood test is not reliable as a
screening test for early detection. CA125 is a marker
for ovarian or endometrial cancers. However, it can al-
so be elevated by uterine fibroids, endometriosis, pelvic* Correspondence: webergf@UCMAIL.UC.EDU
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reproduction in any medium, provided the originflammatory disease and cirrhosis, as well as in preg-
nancy and during menstruation.
While biomarkers for specific types of cancer have
value, markers that detect multiple cancers may be more
beneficial in diagnostic screening, where it is impractical
to have one marker for every possible cancer. As such,
gene products of cancer progression often are generated
as splice variants that are absent from untransformed
tissues. Because the same mechanisms for progression
are used by various cancers these molecules may broadly
indicate the presence of a cancer in the patient.
Osteopontin has been associated with the progression
of numerous types of cancer (Weber et al. 2010; Weber
et al. 2011; Weber 2011). Although the molecule has
been studied as a marker for malignancy over more than
20 years (Craig et al. 1988; Senger et al. 1989) it has
not yet found clinical use as a diagnostic. The full-length
form of osteopontin (osteopontin-a) acts as a TH1 cyto-
kine that may be secreted by macrophages and T-lym-
phocytes and is elevated in the blood during immuneThis is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
inal work is properly cited.
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identified the splice variant osteopontin-c (He et al. 2006)
to be selectively present in multiple cancers (Sullivan et al.
2009; Tilli et al. 2011) and to serve as a marker for tumor
grade (Mirza et al. 2008). These studies were done by im-
munohistochemistry or real-time RT-PCR on the cancer
tissues. The value of the biomarker may be increased if it
can be identified in patient blood and can be correlated to
clinical determinants of cancer. Because we had previously
developed a real-time RT-PCR protocol to quantify the
RNA messages of all three osteopontin splice variants in
breast cancer specimens, we adapted it to the analysis of
total RNA extracted from whole blood. We tested the hy-
pothesis that aggressive cancers continuously shed cells
into the circulation, which are detectable by their unique
production of spliced osteopontin mRNA.
Materials and methods
Patients
Patient samples were obtained under IRB (Institutional
Review Board) protocols 04-01-29-01 and 09-11-09-03
(University of Cincinnati). There were several sources of
patient blood. Whole blood was collected from breast
cancer patients after obtaining informed consent. The
blood was frozen immediately on dry ice. Some blood
samples (including pancreatic and gynecologic cancers)
were also obtained from CHTN (Collaborative Human
Tissue Network). Pelleted nucleated cells from lung can-
cer patients were provided by the University of Cincinnati
tissue procurement service. Blood RNA from breast can-
cer patients and normal controls was obtained from the
Division of Human Genetics at The Ohio State University.
Other cancers entailed 1 hepatocellular carcinoma and 2
colorectal adenocarcinomas.
RNA extraction
RNA was extracted from whole blood with RNazol RT
(Molecular Research Center Inc.). The extraction of RNA
from nucleated cells was accomplished with TriReagent-
RT Blood (Molecular Research Center Inc.). No RNA
extraction was required for the Ohio State University
samples, as they were provided as RNA samples.
Real-time RT-PCR
All PCR reactions were performed on an ABI Prism
7000 cycler using SYBR Green detection format. cDNA
was made from 1 μg RNA in a 20 μl reaction using the
iScript reverse transcription kit (BioRad). 5 μl (for actin
2.5 μl) cDNA was added to each PCR reaction in a total
volume of 25 μl using the standard PCR buffer system
with optimized concentrations of MgCl2. For each expe-
riment a no-template reaction was included as a negative
control. cDNA from MDA-MB-435 cells, which exp-
ress endogenous osteopontin splice variants, served as areference in every run. The primer combinations were
described previously (Mirza et al. 2008). The conditions
for PCR were 94°C denaturation for 120 s followed by
40 cycles of: 94°C melting for 15 s, 58°C annealing for
30 s, extension at 72°C for 30 s, followed by 72°C for
2 min and 4°C for 5 min, and a melting curve program
(the amplification efficiency was only minimally affected
by using the same annealing temperature for all PCR
reactions, compared to Mirza et al. (2008) which had
optimized the annealing temperatures individually; the
amplification efficiency is accounted for in the calcula-
tions of relative RNA abundance). Product purity, prod-
uct size, and absence of primer dimers were confirmed
by DNA melting curve analysis and agarose gel elec-
trophoresis. Melt curves yielded a single sharp peak for
all template reactions, and a minimal melt peak (resul-
ting from primer dimers) or no melt peaks for the no-
template control reactions (Mirza et al. 2008). Relative
expression ratios of the target genes were calculated
from the cycle threshold and efficiency measurements
(Pfaffl 2001).
To assess the sensitivity of the assay, we titrated MDA-
MB-435 cells, which express all three forms of osteopon-
tin (He et al. 2006) and served here as the reference cell
line, into normal blood. RNA was then extracted for real-
time RT-PCR. The relative abundance was calculated ac-
cording to the method of Pfaffl (2001) using the average
of all undiluted MDA-MB-435 real-time RT-PCR results
(the positive control and reference in all blood RT-PCR
runs) as the reference value.
Statistics
Each data set was analyzed for equality of variances
using the Levene test. The Kolmogorov-Smirnov test
was applied to determine which of the data sets had a
normal distribution. Since none of the datasets followed
a normal distribution, they were analyzed with the
Kruskal-Wallis Test. A significant value (p<.05) signifies
that the medians of the groups being tested are not
equal. The non-parametric test uses medians to test the
groups rather than the means because medians are ro-
bust estimators that are resistant to outliers. In the cases
with the significant results (except for single pairwise re-
sults), a non-parametric procedure was performed in
SAS, PROC MULTTEST, to analyze the differences be-
tween the cancer groups and the control by setting up
individual contrasts. This is analogous to independent t-
tests, in which one controls for the type I error rate
using a method such as bootstrapping. The bootstrap
method is a non-parametric approach involving multiple
re-sampling of the data. Using this SAS procedure, a
reproduction of the Dunnett’s test was set up to deter-
mine the relationship between osteopontin splice variant
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Figure 1 Assay sensitivity. Real-time RT-PCR after titration of
cancer cells (MDA-MB-435) into blood from a healthy donor. Each
data point is the average of three experiments. The PCR reaction
was run over 40 cycles, and the reverse transcription reaction
contained the standard amount of 1 μg RNA in a 20 μl reaction. The
insert shows the data replotted on a double-logarithmic scale. The
x-axis labels are 10×.
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and its associated p-value were calculated.
Results
To assess the sensitivity of the method, we collected
blood from a healthy donor and titrated increasing num-
bers of the cancer cell line MDA-MB-435 into it before
RNA extraction. This cell line is an abundant producer
of all three osteopontin splice variants and therefore al-
lows an estimate of the detection limit of cancer cells in
the blood. Because this quantitative PCR method uses
MDA-MB-435 cells as its reference, the relative RNA
abundance served as a reliable indicator. The actin signal
is generated predominantly by the white blood cells and
stayed constant regardless of the number of cancer cells
added. For each transcript, the CT (cycle threshold) valuesTable 1 Patient demographics
Sex
N Female Male Mean
breast cancer 67 67 0 54.7
lung cancer 45 27 18 61.3
pancreatic cancer 7 4 3 65.3
gynecologic cancers 6 6 0 58.2
other cancers 3 0 3 65
healthy controls 74 62 7 51.1
For each group, the distribution of sex, age, and race is shown (five of the healthy cdropped by about one unit after addition of 100 cancer
cells/ml to the blood. However, at the sensitivity of this
protocol (applying the algorithm for calculating relative
abundance and accounting for assay-to-assay fluctuations)
about 1000 cancer cells are reliably detectable by an ele-
vated signal (Figure 1).
The patient demographics are shown in Table 1. We
first compared the mRNA abundance for osteopontin
splice variants in cancer (breast, lung, pancreatic, gyneco-
logic, other) versus normal (Figure 2). For osteopontin-a,
none of the cancers was significantly different from the
controls. The large increase of osteopontin-a in the mean
value and error bar for lung cancers is caused by an ex-
ceedingly high value in one patient, otherwise there was
no difference from healthy controls. When conside-
ring osteopontin-b, lung cancers, pancreatic cancers,
and other cancers were significantly different from con-
trols. Osteopontin-c displayed significant increases from
the control group in gynecologic (ovarian, cervical, en-
dometrial) and pancreatic cancers. Although the mean
values for osteopontin-c in breast and lung cancers were
elevated 3- to 3.5-fold over healthy controls, they did not
reach significance. To determine the value of osteopontin
splice variants as cancer screening markers, we pooled
all cancers and tested for significant differences according
to the Kruskal-Wallis test. Whereas osteopontin-a was
not significantly different between cancers and controls,
osteopontin-b (p= 0.0005) and osteopontin-c (p < 0.0001)
were significantly elevated in the cancers.
Most of the control samples cluster tightly for all three
splice variants. The markers have high specificity. Yet,
when broadly comparing cancers to controls, the sensi-
tivity is low with only a limited portion of cancer pa-
tients showing elevation of one or several osteopontin
splice variants in the blood. For the two large groups of
breast cancers and lung cancers, we calculated the frac-
tion of patients whose osteopontin RNA message levels
were elevated by one, two, or three standard deviations
above the mean value of the healthy controls (Table 2).
While osteopontin-b and -c capture a fraction of lung can-
cer patients, osteopontin-c captures a fraction of breast
cancer patients. This indicates a heterogeneity withinAge Race
Min Max White Asian Black Unknown
24 86 56 2 3 6
35 82 31 0 8 6
43 85 5 0 0 2
39 78 4 0 1 1
53 78 3 0 0 0
18 85 66 2 2 4
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Figure 2 Osteopontin splice variant RNA in blood. Analysis of
osteopontin splice variant mRNA (mean ± sem) in blood specimens
from breast cancer (n = 67), lung cancer (n = 45), pancreatic cancer
(n = 7), or gynecologic cancer (n = 6) patients and healthy controls
(n = 74). Significance is accepted at the α = 0.05 level. A)
Measurements of osteopontin-a by real-time RT-PCR in all blood
samples. B) Osteopontin-b in various cancers versus healthy controls.
C) Osteopontin-c in various cancers versus healthy controls. The
insert shows the same graph with a logarithmic y-axis. D)
Visualization of representative real-time RT-PCR products by agarose
gel electrophoresis. To confirm the integrity of the PCR products, a
representative cancer specimen was compared to a representative
healthy control. The cell line MDA-MB-435 and no template (H2O)
served as positive and negative controls respectively. a = ostepontin-a,
b = ostepontin-b, c = ostepontin-c, ac = β-actin, m = markers.
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variants to detect subsets within them. Of note, elevation
in osteopontin-b RNA is associated with a large fraction
of lung cancers, with 56% increased by more than one,
42% more than two, and 24% more than three standard
deviations above the mean value of healthy controls.
We asked whether there are differences among the his-
tologic subtypes of lung cancer with regard to the abun-
dance of osteopontin splice variant RNA in the blood.
There were no differences for osteopontin-a, osteopon-
tin-b or osteopontin-c among adenocarcinoma (n = 26),
non-small cell lung cancer (n = 4), and squamous cell car-
cinoma (n = 11) according to the Kruskal-Wallis test
(four lung cancers were diagnosed as carcinoid tumor,
small cell cancer, pleomorphic carcinoma, non-mucinous
bronchioloalveolar carcinoma, and were not included in
this analysis). Similarly, there were no differences in abun-
dance of the splice variants between ductal (n = 58) and
lobular (n = 7) breast cancers (two cancers were muci-
nous carcinomas).
In lung cancers, osteopontin-c increased with higher tu-
mor grades (mean value grade 1 = 0.336, grade 2 = 0.474,
grade 3 = 0.743), however, this fell short of reachingTable 2 Detection cutoffs
breast cancer
OPNa OPNb OPNc
1 std 4% (3) 3% (2) 28% (19)
2 std 3% (2) 1% (1) 15% (10)
3 std 3% (2) 0% (0) 13% (9)
lung cancer
OPNa OPNb OPNc
1 std 7% (3) 56% (26) 38% (17)
2 std 4% (2) 42% (19) 16% (7)
3 std 2% (1) 24% (11) 7% (3)
Percentage (and in parentheses number) of breast cancer or lung cancer
patients above a threshold of 1, 2 or 3 standard deviations above the mean
value of healthy controls.
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ation between the levels of osteopontin splice variants and
either primary tumor size or tumor stage (Table 3A). In
breast cancers, there was no correlation between the levels
of osteopontin splice variants and either primary tumor
size or tumor stage T or tumor stage N (Table 3B). There
was also no correlation with tumor grade (Figure 3A). In
situ carcinomas are early forms of breast cancer, which
are characterized by the absence of tumor cell invasion






















































Figure 3 Osteopontin splice variant RNA in tumor progression. A) Ost
(top panel) and breast cancers (bottom panel). B) The levels of osteopontin
situ carcinomas and breast cancers. Diamonds are individual data points, h
ostepontin-a = 0.004, ostepontin-b = 0.016, ostepontin-c = 0.216).and osteopontin-c, but not osteopontin-b, increased from
in situ carcinomas to breast cancers (Figure 3B). However,
osteopontin-a again showed wide variations with only two
patients having dramatically elevated levels. Initially, the
paucity of a correlation between osteopontin splice variant
expression and tumor progression may be surprising be-
cause more cells might be expected to enter the circula-
tion after tumor growth or tumor spread. However, it has
been reported that cancers, and even non-transforming





























a i.s. ca i.s.
p<0.05
ca = cancer
i.s. = in situ carcinoma
eopontin splice variant levels and tumor grade in lung cancers
-a, osteopontin-b, and osteopontin-c in blood from patients with in
orizontal lines represent the mean values (the in situ mean values are
Table 3 Cancer stage and primary tumor size
A. lung cancer
lung cancer stage OPNa OPNb OPNc
correlation coefficient 0.127 0.172 0.185
p-value 0.480 0.339 0.304
lung cancer size OPNa OPNb OPNc
correlation coefficient -0.193 -0.508 -0.012
p-value 0.259 0.002 0.942
B. breast cancer
breast cancer stage T OPNa OPNb OPNc
correlation coefficient 0.223 0.123 0.087
p-value 0.084 0.343 0.507
breast cancer stage N OPNa OPNb OPNc
correlation coefficient 0.078 -0.084 0.161
p-value 0.561 0.530 0.227
breast cancer size OPNa OPNb OPNc
correlation coefficient -0.070 -0.090 0.111
p-value 0.585 0.480 0.385
To determine the relationship between osteopontin splice variant levels and tumor stage or primary tumor size, Spearman’s correlation coefficient and its
associated p-value were calculated. For lung cancers (A), stage I-IV was used (n = 10, 6, 11, 6 for I, II, II, IV). For breast cancers (B), stage T (n = 37, 16, 8, 2 for T1,
T2, T3, T4) and N (n = 28, 20, 5, 7, 0 for N0, N1, N2, N3, N4) were applied to the analysis. Of note, the significant p-value is not reflective of a strong correlation. It
indicates that the population correlation coefficient is different than zero with the degree of confidence given by the p-value.
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suggesting that the burden of circulating cells need not
correlate with tumor size or stage.
Information on conventional biomarkers was available
for several tumors. In the lung cancers, there was no dif-
ference in osteopontin-a, osteopontin-b or osteopontin-c
between the TFF1+ (n = 12) and the TFF1- (n = 10) sub-
groups or between the P63+ (n = 8) and P63- (n = 5)
subgroups. There were also no differences in osteopon-
tin splice variant levels between CK-7+ (n = 12) and
CK-7- (n = 3) lung cancers or between CK-5/6+ (n = 2)
and CK-5/6- (n = 5) lung cancers. ER, PR, and HER2 are
standard biomarkers for breast cancer that determine
treatment decisions. Again, osteopontin-a displayed a
wide scatter with outlier samples in the marker-positive
and marker-negative groups. In this analysis, osteopon-
tin-c also had one outlier with a high value in the ER-
PR- breast cancer group and no significant differences
between the groups (not shown). The only significant
difference detected was for osteopontin-b between ER-
(mean value 0.0098, n = 13) and ER+ (mean value 0.004,
n = 49) breast cancers, the relevance of which remainsto be elucidated as osteopontin-b was not found to be
elevated in breast cancers over control specimens.
Discussion
Here we describe the real-time RT-PCR detection of os-
teopontin splice variants in whole blood. While osteo-
pontin-b is a marker for lung cancers and pancreatic
cancers. osteopontin-c is increased in gynecologic and
pancreatic cancers. However, osteopontin-c also detects
fractions of breast cancers and of lung cancers, sugges-
ting heterogeneity within those types of tumors.
Possibly the most striking and unexpected finding
of this study was the elevation of osteopontin-b in the
blood of a large fraction of lung cancer patients (over
55% elevated more than one standard deviation above the
healthy mean value). Osteopontin-b RNA in the blood is a
biomarker for lung cancers. Although osteopontin-c was
not identified as a marker when considering all lung can-
cers together, close to 40% of patients had elevated levels
of at least one standard deviation above the healthy mean
value, and there was a trend toward higher osteopontin-c
levels in higher grade cancers. By ELISA (which does not
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levels of osteopontin protein have been found to be asso-
ciated with lung cancer (Chang et al. 2007; Mountzios
et al. 2007; Fedarko et al. 2001) and to be predictors of
prognosis (Mack et al. 2008). Of note, the osteopontin
protein levels in the blood are likely mostly generated by
the primary cancer or its established metastases, whereas
the blood RNA levels are thought to come entirely from
circulating tumor cells.
In breast cancer tissue, osteopontin-c (measured by
real-time RT-PCR or immunohistochemistry) is present
in over 75% of cases and serves as a marker of tumor
grade (Mirza et al. 2008). Unexpectedly, the blood real-
time RT-PCR measurements of this study did not find
the same correlations. Only about 30% of breast can-
cers generated blood levels of osteopontin-c that excee-
ded one standard deviation above the mean value of
healthy controls. Clearly, breast cancers were associated
with higher osteopontin-c blood RNA levels than in situ
carcinomas. Osteopontin-c showed no association with
ER, PR, or HER2. While this is in line with its previously
reported association with triple negative breast cancer
(Mirza et al. 2008; Weber 2011; Weber et al. 2011), there
were only five triple negative breast cancers in this
study - too few to confirm any association with this
subset. Further investigations are required to elucidate
the subfractions of breast cancers that cause elevated
blood mRNA for osteopontin-c. We have previously
found osteopontin-b in breast tissue not to be a marker
for breast cancer (Mirza et al. 2008). Consistently, the
mean value of osteopontin-b in all breast cancers is not
elevated over the mean value in healthy controls, and
osteopontin-b does not increase in cancer over in situ
carcinomas. Therefore, the difference in osteopontin-b
levels between ER+ and ER- breast cancers is surprising.
As neither subgroup has significantly higher osteopon-
tin-b values than healthy controls, the difference is not
of diagnostic value for cancer.
Our protocol was intended to provide a sensitive screen-
ing test that may detect the presence of cancer (without
selectivity for a particular type of cancer). While the ap-
proach has high specificity, with the available technology
it has limited sensitivity. Rather than standing alone as
diagnostics in screening, osteopontin splice mRNA blood
levels may find use in monitoring cancer progression or in
multi-marker panels (see Weber 2011).
For diagnostic applications, it is important that a clin-
ical test be robust to differences in the initial processing
of the blood. The material analyzed here came from
multiple sources. With the exception of the nucleated
cell preparations, all sources of blood RNA had es-
sentially identical mean values and standard deviations
for their osteopontin-a and -b real-time PCR results.
The RNA extracted from nucleated cells yielded highervalues for osteopontin-a and osteopontin-b than the
RNA from other sources. We believe this to reflect the
high proportion of lung cancers in this sample set rather
than a bias in methodology. The samples obtained from
CHTN had higher ostoepontin-c measurements than the
other sources. Again, that is likely reflective of the can-
cer selection (all the non-lung, non-breast samples came
from that source). CHTN was the only provider that did
not guarantee a short time window from blood drawing
to freezing. Initially, degradation of osteopontin RNA
was a substantial concern. The high values imply that
RNA may be more stable after phlebotomy than is ge-
nerally assumed. Blood RNA, while stable in situ, is
believed to degrade rapidly once the blood is drawn. Al-
though we could not detect apparent differences among
the samples from various sources, there was a clear loss
of osteopontin RNA species (but not of β-actin) when
cDNA was thawed for the third time. This loss amounted
to an increase in the CT value of 5–10 cycles. Hence,
there is limited stability of the osteopontin splice cDNA,
which may lead to underestimation if samples are handled
improperly. Over 18 runs, the cycle threshold readings
for the reference cell line MDA-MB-435 were stable for
actin (13.2-14.6), osteopontin-a (13.2-16.7), osteopontin-b
(13.6-15.8), and osteopontin-c (13.3-17.1). The data were
analyzed by calculating a relative ratio R in various diffe-
rent ways. The method described by Pfaffl (2001) was su-
perior. It uses the amplification efficiencies E and the







A flexible threshold (set as the inversion point on the
logarithmic plot of the amplification curves) did not
improve the readings over a fixed threshold. A conven-
tional comparative threshold method is similar to the one
used here, but neglects to account for differences in amp-
lification efficiencies by setting E = 2.
Conclusion
Osteopontin-b and -c in the blood are biomarkers for
distinct cancers. Osteopontin-b is increased in lung can-
cer patients and pancreatic cancer patients. Osteopon-
tin-c is increased in gynecologic and pancreatic cancers,
as well as a fraction of breast cancers and lung can-
cers. Specifically, breast carcinomas are associated with
significantly higher levels of osteopontin-c mRNA in the
blood than carcinomas in situ. In lung cancer patients, the
osteopontin-c blood RNA levels have an increasing trend
with tumor grade. Our investigations may have bearing on
cancer screening and diagnosis.
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